Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

Core Insights - Poseida Therapeutics is presenting new preclinical data on allogeneic CAR+TCR-T cells that are rich in stem cell memory T cells (TSCM) and have enhanced potency for targeting solid tumors at the SITC 39th Annual Meeting [1] - The company will also present additional profiling of patient responses from the P-BCMA-ALLO1 Phase 1 Arm C and preclinical data from P-CD19CD20-ALLO1 at the ASH Annual Meeting [2] Group 1: Product Development - P-BCMA-ALLO1 is an investigational non-viral TSCM-rich allogeneic CAR-T therapy currently in Phase 1/1b clinical development targeting BCMA for relapsed/refractory multiple myeloma [3] - P-CD19CD20-ALLO1 is the first allogeneic dual CAR-T cell product candidate targeting both CD19 and CD20 antigens for relapsed or refractory B-cell malignancies [3][8] - Both P-BCMA-ALLO1 and P-CD19CD20-ALLO1 are being developed in collaboration with Roche to address hematologic malignancies [3] Group 2: Upcoming Presentations - At SITC 2024, a poster presentation titled "Multi-antigen Targeting with CAR and TCR Co-expression in Allogeneic Cell Therapy for Solid Tumors" will be presented on November 9, 2024 [4] - At ASH 2024, multiple poster presentations will highlight clinical data from P-BCMA-ALLO1 and preclinical data from P-CD19CD20-ALLO1, scheduled for December 7-9, 2024 [5][6] Group 3: Regulatory Designations - P-BCMA-ALLO1 has received Orphan Drug designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for adult patients with relapsed/refractory multiple myeloma after three or more prior lines of therapies [6] - The investigational therapy is believed to address unmet needs in multiple myeloma, supported by interim clinical data [6] Group 4: Company Overview - Poseida Therapeutics is a clinical-stage biopharmaceutical company focused on advancing differentiated allogeneic cell therapies and genetic medicines [9] - The company utilizes proprietary genetic editing platforms and has formed strategic collaborations with Roche and Astellas to enhance cell therapy development [9]